The Rise of Immune Engagers: Strategic Implications for Pharma R&D and Licensing
The landscape of oncology is undergoing a profound transformation driven by immunotherapy innovation. Over the past decade, immune checkpoint inhibitors, CAR-T therapies, and antibody-drug conjugates
